TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9196609
Drug: Corticotropin releasing
Normalized name: Corticotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin releasing hormone (CRH) (1 microgram/kg i.v.)
Study: 8453437
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, three times a day for six weeks)
Study: 3743143
Drug: Intranasal occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal occlusion with petrolatum gauze
Study: 3743143
Drug: Intranasal occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal occlusion
Study: 26547424
Drug: S‐1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 plus paclitaxel (daily oral S‐1 at 80 mg/m² for 2 weeks plus paclitaxel at 50 mg/m² on days 1 and 8, every 3 weeks)
Study: 26547424
Drug: Paclitaxel (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (weekly administration at 80 mg/m² three times every 4 weeks)
Study: 17925000
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no treatment (controls)
Study: 15717139
Drug: Cisapride 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.3 mg/kg daily
Study: 15717139
Drug: Cisapride 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.6 mg/kg daily
Study: 15717139
Drug: Cisapride treatment
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride treatment
Study: 9393335
Drug: Whole-cell DTP
Normalized name: ActHIB with Whole-Cell DTP Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell DTP vaccine (n = 20,720)
Study: 9393335
Drug: Five-component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-component acellular DTP vaccine (n = 20,747)
Study: 9393335
Drug: Three-component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-component acellular DTP vaccine (n = 20,728)
Study: 9393335
Drug: Two-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component acellular DTP vaccine (n = 20,697)
Study: 7514842
Drug: PPSA (polyclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSA (polyclonal antibodies)
Study: 7514842
Drug: MPSA (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPSA (monoclonal antibodies)
Study: 3605184
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg per day of warfarin for 18 months
Study: 10651597
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and standardized knee exercise program
Study: 30472808
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of proton pump inhibitors
Study: 26662809
Drug: Multi-dimensional Treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dimensional Treatment Foster Care (MTFC)
Study: 24436354
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (70 mL of concentrated beetroot juice containing a minimum of 0.3 g of nitrate)
Study: 24436354
Drug: Placebo (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (70 mL of placebo)
Study: 22810982
Drug: MNP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNP group (maize porridge with multi-micronutrient powder containing 2.5 mg iron as NaFeEDTA; 6.6 mg iron/meal)
Study: 22810982
Drug: Amaranth group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaranth group (unrefined maize 30% and amaranth grain 70% porridge; 23 mg iron/meal)
Study: 22810982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unrefined maize porridge; 4.1 mg iron/meal)
Study: 20599002
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day and Ezetimibe 10 mg/day
Study: 16920077
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1.5 g/d; .84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid)
Study: 16247531
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on ZEEPe
Study: 16247531
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on PEEPe
Study: 16247531
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PEEPe and fenoterol
Study: 12453332
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m2 twice daily for 14 days, every 3 weeks)
Study: 7887554
Drug: Trimethoprim‐sulfamethoxazole (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (one double‐strength tablet daily, five times a week)
Study: 2487803
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg)
Study: 2487803
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg) + Captopril (50 mg)
Study: 775145
Drug: ampicillin‐cloxacillin (Rectocillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin‐cloxacillin (Rectocillin) 1 g/day
Study: 775145
Drug: ampicillin (AB‐PC)
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ampicillin (AB‐PC) 1 g/day
Study: 31996367
Drug: ETN administered
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN administered first line
Study: 31094901
Drug: Intravenous vortioxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vortioxetine 17 mg
Study: 28067119
Drug: ATV 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 400 mg daily (switch)
Study: 28067119
Drug: ATV/r 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r 300/100 mg daily (control)
Study: 17692718
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg QD
Study: 17692718
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 2.0 mg BID
Study: 17692718
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg BID
Study: 11704494
Drug: Inactive ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ultrasound (US) treatment
Study: 3660329
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids supplementation (2.880 g/day for 12 weeks)
Study: 29614582
Drug: Bifidobacterium tetragenous
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium tetragenous viable bacteria tablets
Study: 21621252
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of omega-3 PUFA (1 to 8 g daily over 24 weeks)
Study: 10980764
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Foscarnet sodium and ganciclovir sodium as therapy for newly diagnosed CMV retinitis
Study: 1333071
Drug: 71.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 71.5 Gy in 52 fractions of 1.375 Gy given twice a day (hyperfractionated radiotherapy)
Study: 3882307
Drug: Guanfacine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine, 1 to 3 mg/day
Study: 3882307
Drug: Clonidine, 0.1
Normalized name: Clonidine, 0.1 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.1 to 0.3 mg twice a day
Study: 31271210
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy for insomnia (bCBTi)
Study: 31271210
Drug: Treatment-as-usual for
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual for MDD and/or PTSD
Study: 26184510
Drug: eGFR <45
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <45 ml/min/1.73 m(2)
Study: 17288694
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg QD
Study: 15354280
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 mg twice daily
Study: 15354280
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 mg and 6 mg
Study: 12060615
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (AIT) with tumor-associated lymphocytes (TALs) plus low-dose cisplatinum/5-fluorouracil chemotherapy
Study: 10102433
Drug: Natalizumab (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (0.03 to 3.0 mg/kg)
Study: 10102433
Drug: Natalizumab (1-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (1- or 3-mg/kg IV dose)
Study: 7459895
Drug: Single large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single large dose of misonidazole
Study: 7459895
Drug: Multiple smaller
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple smaller doses of misonidazole
Study: 25664595
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic acid (TUDCA) 1 g twice daily for 54 weeks
Study: 24944242
Drug: V2R agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: V2R agonist (0.2 mg desmopressin)
Study: 24944242
Drug: V2R antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: V2R antagonist (30 mg tolvaptan)
Study: 22113708
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg day(‐1)) for 1 month
Study: 10376613
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg daily for 5 years)
Study: 9219046
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean dose of 166 mg/day)
Study: 9219046
Drug: Chlorpromazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (mean dose of 310 mg/day)
Study: 7524888
Drug: Busulphan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan (1 mg/kg orally QID days -7 to -4) and cyclophosphamide (60 mg/kg IV days -3 and -2) chemotherapy
Study: 7524888
Drug: Post-transplant G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant G-CSF
Study: 29569449
Drug: Non-restorative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-restorative therapy
Study: 15677778
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg once daily and lisinopril 20 mg once daily
Study: 15677778
Drug: Lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40 mg once daily
Study: 12216507
Drug: Preoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative ketamine (0.15 mg/Kg i.v.)
Study: 12216507
Drug: Postoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative ketamine (0.15 mg/Kg i.v.)
Study: 5662989
Drug: Fried onions
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried onions (60 g)
Study: 5662989
Drug: Boiled onions
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled onions (60 g)
Study: 27206943
Drug: ETC-1002 120
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 120 mg
Study: 27206943
Drug: ETC-1002 180
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 180 mg
Study: 26386764
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg/day)
Study: 23048056
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (150 mg/day)
Study: 23048056
Drug: CYP2C19*2 noncarriers
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*2 noncarriers (high-dose clopidogrel)
Study: 23048056
Drug: CYP2C19*2 carriers
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*2 carriers (high-dose clopidogrel)
Study: 19745764
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg oral once daily
Study: 10459091
Drug: Warmed normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed normal saline solution
Study: 9832663
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature saline solution
Study: 8682087
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment in autoreactive forms of myocarditis
Study: 8682087
Drug: Hyperimmunoglobulin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmunoglobulin therapy
Study: 8682087
Drug: Immunomodulating factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating factors (e.g., ribaverin, interleukins, interferons)
Study: 25139178
Drug: Alprazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.75 mg
Study: 7480549
Drug: Alprazolam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.5 mg
Study: 174489
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside ointment
Study: 345534
Drug: Idoxuridine ointment
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idoxuridine ointment
Study: 31103365
Drug: GEN-003 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 (60 µg antigen/50 µg M2)
Study: 31103365
Drug: GEN-003 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-003 (60 µg/75 µg M2)
Study: 28969328
Drug: Viscoelastometry guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastometry guided fresh frozen plasma (FFP) infusion
Study: 25533539
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) titrated to effect, starting at 4.5 g/night and adjusted based on clinical response, for a duration of 12 weeks.
Study: 21338492
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided fascia iliaca block using levobupivacaine, plus spinal anaesthesia with hyperbaric bupivacaine containing no morphine
Study: 21338492
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound guided fascia iliaca block performed with sterile saline, and spinal anaesthesia containing hyperbaric bupivacaine and 0.1 mg of spinal morphine
Study: 16988939
Drug: Interpersonal counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal counseling (IPC), 1 to 6 weekly sessions, telephone-administered
Study: 15188834
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist stimulation test (GAST)
Study: 24084071
Drug: LABA step-up
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LABA step-up therapy
Study: 24084071
Drug: LTRA step-up
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LTRA step-up therapy
Study: 24084071
Drug: ICS step-up
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICS step-up therapy
Study: 30760509
Drug: Palivizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (15 mg/kg)
Study: 8731298
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) 160 UaXa IC/kg/day (group IA)
Study: 8731298
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (LMWH) 320 UaXa IC/kg/day (group IB)
Study: 8731298
Drug: Intravenous non-fractioned
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous non-fractioned heparin (NFH) 100UI/kg (bolus), followed by 1000UI/h
Study: 26269615
Drug: Dulaglutide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.5 mg/kg/dose
Study: 26269615
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg/kg/dose
Study: 26269615
Drug: Dulaglutide 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 5.0 mg/kg/dose
Study: 21995648
Drug: Colistin methanesulfonate
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, twice daily repeat doses
Study: 21995648
Drug: Colistin methanesulfonate
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, single dose
Study: 10679652
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day megestrol acetate (low dose)
Study: 10679652
Drug: 640 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg/day megestrol acetate (high dose)
Study: 10072958
Drug: Domestic bendazac
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic bendazac lysine tablet
Study: 10072958
Drug: Imported bendazac
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported bendazac lysine tablet
Study: 11072419
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg (placebo)
Study: 3602266
Drug: Caffeine 125
Normalized name: caffeine 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 125 mg
Study: 8446671
Drug: Caffeine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (any dose)
Study: 28289240
Drug: Paracetamol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (6 g daily for 3 days)
Study: 21328205
Drug: Multi-sensory environment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-sensory environment therapy (24 sessions over 12 weeks)
Study: 16371613
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg x kg(‐1) fentanyl and 0.02 mg x kg(‐1) midazolam intravenously
Study: 12723100
Drug: New Braun
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Braun Oral‐B Battery (D4) toothbrush
Study: 12723100
Drug: Worn Braun
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worn Braun Oral‐B Battery (D4) toothbrush
Study: 8396608
Drug: 0.1% all-trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% all-trans retinoic acid cream
Study: 8396608
Drug: 0.1% CD271
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% CD271 gel
Study: 3085363
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg b.d. ranitidine
Study: 3085363
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg b.d. ranitidine
Study: 3085363
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg nocte ranitidine for prophylaxis
Study: 3085363
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nocte ranitidine for prophylaxis
Study: 28755285
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice daily)
Study: 24991872
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEEs, 0.625 mg/day)
Study: 24991872
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens and medroxyprogesterone acetate (MPA, 2.5 mg/day)
Study: 23469188
Drug: Clinically integrated
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically integrated post‐graduate training programme in evidence-based medicine (5-day training including assignments, peer teaching, interactive training, lectures, brainstorming sessions)
Study: 20962743
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum bicarbonate levels (20-30 mmol/l)
Study: 20962743
Drug: Serum bicarbonate
Normalized name: BICARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bicarbonate levels near 28-30 mmol/l
Study: 16611442
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (locally manufactured SP tablet formulation, 500 mg sulfadoxine and 25 mg pyrimethamine)